TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
| Revenue (TTM) | $727.65M |
| Gross Profit (TTM) | $426.43M |
| EBITDA | $125.56M |
| Operating Margin | 13.90% |
| Return on Equity | 31.90% |
| Return on Assets | 4.39% |
| Revenue/Share (TTM) | $21.11 |
| Book Value | $15.86 |
| Price-to-Book | 4.62 |
| Price-to-Sales (TTM) | 4.21 |
| EV/Revenue | 4.169 |
| EV/EBITDA | 21.40 |
| Quarterly Earnings Growth (YoY) | -30.30% |
| Quarterly Revenue Growth (YoY) | 41.10% |
| Shares Outstanding | $34.56M |
| Float | $33.62M |
| % Insiders | 3.71% |
| % Institutions | 102.75% |
Volatility is currently expanding
TransMedics Group NASDAQ: TMDX raised its full-year revenue outlook after reporting record third-quarter revenue and transplant case volume, as gains in its liver and heart businesses helped offset a decline in U.S. deceased donor volume.
Three stocks are seeing unusual options activity following their quarterly earnings reports: DraftKings Inc (NASDAQ:DKNG), TransMedics Group Inc (NASDAQ:TMDX), and Omada Health Inc (NASDAQ:OMDA).
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
TransMedics Group, Inc. (TMDX) Q3 2026 Earnings Call Transcript
Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts ANDOVER, Mass., Nov. 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2026.
TMDX's OCS technology, robust pipeline and global expansion support growth prospects, but margin pressures and rising investments remain key concerns.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for TransMedics (TMDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
LOS ANGELES--(BUSINESS WIRE)---- $TMDX--TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law.
ANDOVER, Mass., Oct. 30, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 28, 2026, the Company granted non-qualified stock options to purchase an aggregate of 71,815 shares of its common stock and an aggregate of 47,924 restricted stock units (RSUs) to nine employees.
ANDOVER, Mass., Oct. 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in three upcoming investor conferences.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TMDX and any ticker you trade — then tracks every position and per-strategy win rate.
